Relevance of the Evaluation Criteria Used in Clinical Trials for Alzheimer's Disease

The roundtable 1 “Relevance of the evaluation criteria used in clinical trials for Alzheimer's disease” made reference to the guideline published by the EMEA (European Medicines Agency) in July 2008 on the development of new treatments for Alzheimer's disease (AD) and other dementias, and addressed principally two of the three indications listed in the guideline: symptomatic improvement and disease-modification (primary prevention was hardly discussed). The discussions focussed on two main aspects: improvement of the selection of patients in clinical trials and clinical evaluation and biomarkers. The following suggestions were made: